Search the Newsreel

Bodhi Tree Multimedia Q1 Results: Revenue up 72%, EBITDA rises 161%

ImpediMed Limited (ASX:IPD)Chases FY28 Breakeven for SOZO as Capital Raise Resets the Balance Sheet

Bodhi Tree Multimedia consolidated net profit rises 46.51% in the June 2026 quarter

Archimedes Tech SPAC Partners II Reports Q2 2026 10-Q with Significant PIPE-Related Losses

Archimedes Tech SPAC Partners II reported a significant net loss of $135,048,119 for the first half of 2026, primarily due to a $100,000,000 PIPE subscription expense and a $37,942,000 adjustment in the fair value of a PIPE subscription derivative liability. This contrasts sharply with …

Archimedes Tech SPAC III (ARCI) shows $280M in trust and Q2 2026 net income

Archimedes Tech SPAC Partners III Co. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026

Archimedes Tech SPAC (ATII) details $1.2B Forge Nano deal and $135M loss

Archimedes Tech SPAC Partners II Co. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026

CalciMedica shares see H.C. Wainwright neutral rating reiterated

H.C. Wainwright has reiterated a Neutral rating on CalciMedica (NASDAQ:CALC) following the company's second-quarter financial results. The company reported a wider-than-expected loss of $0.45 per share for Q2 2026 and ended the quarter with $18.6 million in cash, which is expected to fund operations …

Price to book forward of CalciMedica, Inc. – BOATS:CALC

The article provides a financial data point for CalciMedica, Inc. (CALC) related to its "Price to book forward" metric. It appears to be a stub or partial financial report from TradingView, indicating the company's market status and some basic financial information without further details …

Is DXCM Stock Worth Buying as Growth Improves but Valuation Stretches?

DexCom, Inc. DXCM is entering the second half of 2026 with healthier margins, broader reimbursement and a larger continuous glucose monitoring opportunity. The investment question is whether that improving setup is enough to justify a premium valuation. Growth catalysts remain visible across U.S. coverage, …

CalciMedica Releases Q2 2026 Financial Results

CalciMedica (CALC) reported a wider net loss of $7.7M, or $0.45 per share, for Q2 2026, an increase from $0.40 per share in Q2 2025. This reflects continued investment in its biopharmaceutical pipeline and the capital-intensive nature of clinical-stage development. Despite the losses, analyst …

MiMedx Group (SMTI partner) clarifies Sanara merger fees and $33 cash-plus-stock deal

MiMedx Group has clarified the termination fees for its merger with Sanara MedTech Inc., stating Sanara would owe $9.66 million in specific cases and MiMedx $22.54 million if it fails to close. The deal offers Sanara shareholders $33.00 cash plus 0.4735 shares of MiMedx …

MiniMed Poised to Roll Out New Innovations in Diabetes Devices but Has Yet to Dig a Moat

MiniMed, recently spun out from Medtronic, is focusing on innovation in diabetes device technology. The company, a leader in durable, tubed insulin pumps for Type 1 diabetes, faces increasing competition despite its historical market presence. An analyst note initiates coverage with a "no-moat" rating …

CalciMedica, Inc. 2Q 2026: Net loss $7.7M, EPS $(0.45) — 10-Q Summary

CalciMedica, Inc. reported a net loss of $7.7 million for the second quarter of 2026, an increase from the $6.0 million loss in the prior year, with diluted loss per share at $(0.45). The company's clinical development is focused on Auxora and CM5480, with …

Sanara MedTech (SMTI) sets $33 cash plus MiMedx stock merger terms and corrects fees

Sanara MedTech Inc. has confirmed the terms of its merger with MiMedx Group, Inc., where each Sanara share will convert into $33.00 in cash and 0.4735 shares of MiMedx common stock, valued at $2.00 per share. This amendment also corrects previously misstated termination fees, …

CalciMedica Q2 FY26 net loss widens to $7.65 million

CalciMedica reported a widened net loss of $7.65 million for Q2 FY26, up from $5.96 million in the prior year, with loss per share increasing to $0.45. Despite this, the company saw a significant reduction in R&D and G&A expenses and increased its cash …

CalciMedica stock gains 6% despite earnings miss on pulmonary trial

CalciMedica (NASDAQ:CALC) reported a second-quarter loss of $0.45 per share, missing analyst estimates, yet its stock rose 6.22% in pre-market trading. The increase was driven by investor focus on the company's advances in its pulmonary hypertension program and regulatory progress, including FDA alignment for …

CalciMedica GAAP EPS of -$0.45 misses by $0.16

* CalciMedica press release [https://seekingalpha.com/pr/20614225-calcimedica-reports-second-quarter-2026-financial-results-and-provides-clinical-and-corporate] (CALC [https://seekingalpha.com/symbol/CALC]): Q2 GAAP EPS of -$0.45 misses by $0.16. * Cash Position: Cash and cash equivalents were $18.6 million as of June 30, 2026. The Company expects its cash and cash equivalents to fund its current operating plan …

MiniMed Group (Nasdaq:MMED) - Stock Analysis

This stock analysis report for MiniMed Group (Nasdaq:MMED) provides an overview of the company's financial health, future growth prospects, past performance, and valuation. It highlights recent news including the launch of new insulin pump systems, board changes, and financial results, noting the company is …

BofA Securities Adjusts MiniMed Group Price Target to $24 From $20

BofA Securities has raised its price target for MiniMed Group (MMED) shares to $24 from $20. This adjustment follows UBS initiating coverage on MiniMed Group with a Buy rating and a $25 price target on July 29th. MiniMed Group, a medical technology company specializing …

BofA raises MiniMed Group stock price target to $24 on exchange timing

BofA Securities has raised its price target for MiniMed Group (NASDAQ: MMED) shares to $24 from $20, while maintaining a Buy rating. The increase is attributed to the approaching potential window for Medtronic to exchange its 90% ownership in MiniMed Group for Medtronic shares. …

IRADIMED CORPORATION (NASDAQ:IRMD) Looks Interesting, And It's About To Pay A Dividend

MiMedx Group, Inc Revenue Breakdown – NASDAQ:MDXG

This article provides a revenue breakdown for MiMedx Group, Inc (NASDAQ: MDXG). Last year, the company generated $418.63 million USD in total revenue, with its Wound segment being the top performer, contributing $276.33 million USD. The United States was the greatest regional contributor to …

Archimedes Tech SPAC Partners II Ord Shs (ATII) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for Archimedes Tech SPAC Partners II Ord Shs (ATII), detailing future EPS and revenue growth estimates. It includes current stock data such as market cap and P/E ratio, alongside a list of peer companies for comparison. The information …

iRadimed (NASDAQ:IRMD) Cut to "Hold" at Wall Street Zen

iRadimed (NASDAQ:IRMD) has been downgraded to a "Hold" rating by Wall Street Zen and Weiss Ratings, despite analysts maintaining a "Moderate Buy" consensus with an average price target of $120. The company recently surpassed quarterly earnings and revenue expectations. CEO Roger E. Susi sold …

MiMedx Group Inc (MDXG) Stock News Today

This article from TradingKey provides current stock information for MiMedx Group Inc (MDXG), including its stock price, market cap, and P/E ratio. It notes that more news regarding MDXG's earnings, analyst ratings, and key developments will be available soon. The page serves as a …

IRadimed (IRMD) Q2 2026 Earnings Call Transcript

Image source: The Motley Fool. DATE Friday, July 31, 2026 at 11:00 a.m. ET CALL PARTICIPANTS President and Chief Executive Officer - Roger SusiChief Financial Officer - John Glenn TAKEAWAYS Revenue -- $20.5 million, representing a 0.5% increase from $20.4 million in the second …

MiMedx (MDXG) Q2 2026 Earnings Call Transcript

CalciMedica Inc expected to post a loss of 28 cents a share - Earnings Preview

CalciMedica Inc is projected to report a loss of 28 cents per share, according to this earnings preview. The information was sourced from Refinitiv and distributed via Reuters. Readers can access the full article through TradingView.

Replacement Cycle Anchors IRadimed Corp.’s (IRMD) Long Term Growth

Conestoga Capital Advisors, an asset management company, released its second-quarter 2026 investor letter. A copy of the letter can be downloaded here. The letter reports a positive market shift towards Small Caps, with the Russell 2000 Index achieving its best first half since 1991 …

Reaffirmed 2026 Guidance and Dividend Policy Could Be A Game Changer For IRADIMED (IRMD)

Panvel (PNVL3): 2T com resultados sólidos